Bb Biotech Ag Has Lifted Regeneron Pharmaceuticals (REGN) Stake By $25.80 Million; Last Week CI Financial (TSE:CIX) Analysts

June 22, 2018 - By Nellie Frank

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Logo

Bb Biotech Ag increased Regeneron Pharmaceuticals Inc. (REGN) stake by 36.59% reported in 2018Q1 SEC filing. Bb Biotech Ag acquired 75,000 shares as Regeneron Pharmaceuticals Inc. (REGN)’s stock declined 9.59%. The Bb Biotech Ag holds 280,000 shares with $96.42M value, up from 205,000 last quarter. Regeneron Pharmaceuticals Inc. now has $35.77 billion valuation. The stock increased 0.89% or $2.93 during the last trading session, reaching $331.97. About 557,320 shares traded. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has declined 35.54% since June 22, 2017 and is downtrending. It has underperformed by 48.11% the S&P500. Some Historical REGN News: 21/03/2018 – REGENERON & ALNYLAM: PACT TO DISCOVER NEW TREATMENTS FOR NASH; 03/05/2018 – REGENERON PHARMACEUTICALS INC – QTRLY PRALUENT GLOBAL SALES $60 MLN VS $36 MLN; 03/05/2018 – $REGN Did Len pull a Musk this morning as BTIG analyst described?; 10/03/2018 – PRALUENT REDUCES RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 15 PCT VS PLACEBO IN MULTI-YEAR “OUTCOMES” STUDY – DATA; 18/05/2018 – Regeneron Announces Upcoming Investor Conference Presentation; 10/03/2018 – REGENERON, SANOFI SAY PRALUENT PRICING OFFER TO BE TIED TO INDEPENDENT ICER REVIEW OF NEW RISK REDUCTION DATA; 03/05/2018 – Regeneron Pharma 1Q Net $478M; 24/04/2018 – Biotech stars Schleifer and Yancopoulos share $52M in 2017 compensation, even though Regeneron’s share price swooned Plus $264M for Yancopoulos in vested value; 16/05/2018 – Dupixent(R) (dupilumab) Showed Positive Phase 3 Results in Adolescents With Inadequately Controlled Moderate-To-Severe Atopic Dermatitis; 19/03/2018 – EYLEA® (AFLIBERCEPT) INJECTION DEMONSTRATES POSITIVE TOPLINE RESULTS IN PHASE 3 NON-PROLIFERATIVE DIABETIC RETINOPATHY TRIAL

Among 7 analysts covering CI Financial (TSE:CIX), 3 have Buy rating, 1 Sell and 3 Hold. Therefore 43% are positive. CI Financial had 34 analyst reports since July 22, 2015 according to SRatingsIntel. TD Securities maintained the shares of CIX in report on Friday, November 4 with “Hold” rating. The stock of CI Financial Corp (TSE:CIX) earned “Underperform” rating by RBC Capital Markets on Monday, January 9. The company was upgraded on Friday, November 4 by Canaccord Genuity. The rating was maintained by Scotia Capital with “Sector Perform” on Thursday, November 3. The firm has “Sector Perform” rating given on Friday, February 17 by Scotia Capital. See CI Financial Corp (TSE:CIX) latest ratings:

More news for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) were recently published by: Seekingalpha.com, which released: “Sell Kraft-Heinz At $64-65 – Cramer’s Lightning Round (6/21/18)” on June 22, 2018. Streetinsider.com‘s article titled: “Inovio Pharma (INO) Reports Treatment of First Patient in Immuno-Oncology Study for Glioblastoma (GBM) with INO …” and published on June 21, 2018 is yet another important article.

Among 33 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), 11 have Buy rating, 1 Sell and 21 Hold. Therefore 33% are positive. Regeneron Pharmaceuticals Inc. had 127 analyst reports since July 28, 2015 according to SRatingsIntel. The stock has “Sell” rating by Chardan Capital Markets on Monday, January 25. Oppenheimer maintained Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Thursday, August 3 with “Hold” rating. The stock of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has “Buy” rating given on Tuesday, March 8 by Brean Capital. The stock of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) earned “Hold” rating by Citigroup on Tuesday, January 9. The rating was maintained by Leerink Swann on Monday, August 3 with “Outperform”. The stock of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has “Neutral” rating given on Wednesday, January 24 by JP Morgan. The stock has “Buy” rating by Roth Capital on Monday, April 4. UBS maintained the shares of REGN in report on Wednesday, August 5 with “Sell” rating. The company was upgraded on Monday, September 7 by UBS. On Friday, August 4 the stock rating was maintained by UBS with “Buy”.

Investors sentiment decreased to 1.05 in Q1 2018. Its down 0.12, from 1.17 in 2017Q4. It is negative, as 70 investors sold REGN shares while 158 reduced holdings. 71 funds opened positions while 169 raised stakes. 69.33 million shares or 0.23% more from 69.17 million shares in 2017Q4 were reported. Healthcor Lp owns 625,000 shares. Robeco Institutional Asset Mgmt Bv owns 5,242 shares. Schroder Invest Management Grp Incorporated owns 9,145 shares. 16,599 are held by Halsey Assocs Ct. Td Asset Mngmt reported 48,109 shares. Laurion Capital Mgmt LP has invested 0.02% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Ardevora Asset Mngmt Llp holds 78,300 shares or 0.8% of its portfolio. Millennium Management Limited Co holds 202,346 shares or 0.09% of its portfolio. Shell Asset Communication has 9,988 shares. First Interstate Retail Bank owns 2,183 shares. Eventide Asset Mgmt holds 23,000 shares or 0.37% of its portfolio. Limited Ca holds 8,322 shares or 0.51% of its portfolio. Reliance Of Delaware, a Delaware-based fund reported 1,498 shares. Oakbrook Invs reported 6,465 shares. The Kentucky-based Hl Ltd Com has invested 0.01% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Since February 9, 2018, it had 0 buys, and 6 sales for $48.41 million activity. Shares for $325,600 were sold by GOLDSTEIN JOSEPH L. STAHL NEIL had sold 11,407 shares worth $3.37 million on Wednesday, May 23. Sanofi sold $37.61 million worth of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Friday, June 8. Another trade for 20,000 shares valued at $5.72 million was made by SING GEORGE L on Wednesday, May 9.

Investors sentiment decreased to 0.75 in Q1 2018. Its down 2.08, from 2.83 in 2017Q4. It dived, as 3 investors sold CI Financial Corp shares while 9 reduced holdings. 2 funds opened positions while 7 raised stakes. 1.37 million shares or 0.50% more from 1.36 million shares in 2017Q4 were reported. 16,595 were reported by California Pub Employees Retirement System. Wells Fargo & Com Mn holds 0% of its portfolio in CI Financial Corp (TSE:CIX) for 755 shares. Horrell Capital Mngmt accumulated 10,000 shares. The New York-based Ny State Common Retirement Fund has invested 0% in CI Financial Corp (TSE:CIX). Renaissance Tech Lc reported 0% stake. 111,940 were reported by Blackrock Inc. Morgan Stanley reported 0% stake. Fincl Bank Of Mellon has invested 0% of its portfolio in CI Financial Corp (TSE:CIX). American Gru invested in 0% or 1,055 shares. Goldman Sachs Grp has 17,841 shares for 0% of their portfolio. Legal General Gp Public Ltd reported 0% stake. Royal State Bank Of Canada holds 0% or 47,202 shares. Dimensional Fund Advisors Ltd Partnership invested 0% in CI Financial Corp (TSE:CIX). Deutsche Bancorp Ag holds 4,675 shares. Vanguard Group holds 0% or 11,179 shares in its portfolio.

CI Financial Corp. is a publicly owned asset management holding company. The company has market cap of $6.51 billion. Through its subsidiaries, the firm manages separate client focused equity, fixed income, and alternative investments portfolios. It has a 12.76 P/E ratio. It also manages mutual funds, hedge funds, and fund of funds for its clients through its subsidiaries.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>